CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences: Citi’s 17th Annual BioPharma Conference Dates: Tuesday, Sept. 6, 2022 – Thursday, Sept. 8, 2022 … [Read more…]
EMERYVILLE, Calif.–(BUSINESS WIRE)–Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the “Company” or “Vivani”) announced that trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “VANI” will commence today. Vivani is the combination of Nano Precision Medical, Inc. (“NPM”) and Second Sight Medical Products, Inc. Closing of the … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global DNA Vaccines Market (2022-2027) by Product Type, Type, End-User Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global DNA Vaccines Market is estimated to be USD 477.65 Mn in 2022 and is projected to reach USD 646.47 Mn by 2027, growing … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Europe Antibody Drug Conjugates Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. Major factors that are contributing to the growth of the market include the rising prevalence of cancer across European countries, the increasing geriatric population, and rising investments in research and development activities to develop novel … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Africa Non-Hodgkin Lymphoma Treatment Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027” report has been added to ResearchAndMarkets.com’s offering. The country research report on Africa non-Hodgkin lymphoma treatment market is a customer intelligence and competitive study of the Africa market. Moreover, the report provides deep insights into demand forecasts, market … [Read more…]
MUNICH–(BUSINESS WIRE)–Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Prof. Marion Munk, MD, PhD, FEBO, the CMO of Isarna Therapeutics and a renowned global retina specialist will provide initial positive safety results and efficacy signs … [Read more…]
The IncellDx incellKINE Long COVID In Vitro Diagnostic Receives European CE Marking for Its In Vitro Diagnostic (IVD) for Long COVID The simple blood test detects immune signatures specific to long COVID, enabling it to differentiate long COVID from other diseases with similar symptoms. The test will be launched in September through a strategic partnership … [Read more…]
Long-term findings from the multicentre, international LINC 3 study demonstrated that treatment with Isturisa® (osilodrostat) maintains cortisol normalisation and is well tolerated in most patients with Cushing’s disease. PUTEAUX, France–(BUSINESS WIRE)–Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in … [Read more…]
BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma today announced the appointment of Paul Navarre as new member of its Board of Directors. Paul Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the … [Read more…]
California Assembly Bill 1695 (Miguel Santiago, D-53rd District) makes adaptive reuse of existing buildings permanently eligible for the state’s affordable multifamily housing loan programs The bill, which defines ‘adaptive reuse’ to mean the retrofitting and repurposing of an existing building to create new residential units, cleared the Assembly unanimously earlier today and now heads to … [Read more…]
